New drug could shield heart surgery patients from deadly complications
NCT ID NCT07594509
First seen May 26, 2026 · Last updated Jun 12, 2026 · Updated 4 times
Summary
This study tests whether the drug vericiguat, given before and after heart surgery, can prevent serious problems like heart failure, heart attack, or organ damage. About 600 adults at high risk will either get vericiguat plus standard care or standard care alone. The goal is to see if vericiguat helps patients recover more safely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOPULMONARY BYPASS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, 210029, China
Conditions
Explore the condition pages connected to this study.